Skip to content
10-Q

Quarterly Report

Mineralys Therapeutics, Inc. MLYS

0001933414-26-000084

← back to feed
Filed
May 6, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Apr 27, 2026 82.5M sh
Shares Diluted Q1 2026 · Mar 31, 2026 82.83M sh
Shares Diluted Q1 2026 · Mar 31, 2025 53.16M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$39.47M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$45.49M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $112.78M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $172.92M
Stockholders Equity Q1 2026 · Mar 31, 2026 $638.14M
Stockholders Equity Q1 2026 · Dec 31, 2025 $646.69M
Stockholders Equity Q1 2026 · Mar 31, 2025 $341.56M
Stockholders Equity Q1 2026 · Dec 31, 2024 $191.26M
Current Liabilities Q1 2026 · Mar 31, 2026 $14.72M
Current Liabilities Q1 2026 · Dec 31, 2025 $15.11M
Current Assets Q1 2026 · Mar 31, 2026 $652.47M
Current Assets Q1 2026 · Dec 31, 2025 $661.39M
Total Assets Q1 2026 · Mar 31, 2026 $652.86M
Total Assets Q1 2026 · Dec 31, 2025 $661.81M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.47
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.79
Eps Basic Q1 2026 · Mar 31, 2026 −$0.47
Eps Basic Q1 2026 · Mar 31, 2025 −$0.79
Sga Expense Q1 2026 · Mar 31, 2026 $20.98M
Sga Expense Q1 2026 · Mar 31, 2025 $6.57M
Rd Expense Q1 2026 · Mar 31, 2026 $24.37M
Rd Expense Q1 2026 · Mar 31, 2025 $37.88M
Net Income Q1 2026 · Mar 31, 2026 −$39.34M
Net Income Q1 2026 · Mar 31, 2025 −$42.21M
Operating Income Q1 2026 · Mar 31, 2026 −$45.34M
Operating Income Q1 2026 · Mar 31, 2025 −$44.45M